Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Madrigal Pharmaceuticals
Madrigal Pharmaceuticals
5 Promising MASH Therapies That Could Follow Madrigal’s Rezdiffra
BioSpace
Mon, 04/15/24 - 11:24 am
MASH
NASH
Madrigal Pharmaceuticals
Rezdiffra
Ionis Pharmaceuticals
ION224
Altimmune
pemvidutid
89Bio
pegozafermin
Viking Therapeutics
VK2809
Aligos Therapeutics
ALG-055009
Madrigal’s Rezdiffra Energizes MASH Space, Sets Bar for Future Therapies
BioSpace
Mon, 03/18/24 - 11:25 am
Madrigal Pharmaceuticals
Rezdiffra
NASH
MASH
Madrigal wins FDA approval of first drug for MASH
BioPharma Dive
Thu, 03/14/24 - 06:27 pm
Madrigal Pharmaceuticals
FDA
Rezdiffra
MASH
NASH
4 biotechs to watch in 2024
Pharma Voice
Wed, 02/21/24 - 11:28 am
biotech
IPOs
Alto Neuroscience
Verona Pharma
Karuna Therapeutics
Madrigal Pharmaceuticals
precision medicine
COPD
Alzheimer's disease
NASH
2 Rising Biotechs That Could Become the Next Novo Nordisk
Motley Fool
Mon, 01/29/24 - 11:04 am
Novo Nordisk
Madrigal Pharmaceuticals
Viking Therapeutics
NASH
5 FDA Decisions to Watch in Q1
BioSpace
Tue, 01/2/24 - 11:24 am
FDA
Iovance Biotherapeutics
melanoma
lifileucel
Minerva Neurosciences
schizophrenia
roluperidone
Viatris
Mapi Pharma
MS
multiple sclerosis
GA Depot
Madrigal Pharmaceuticals
NASH
resmetirom
Vertex Pharmaceuticals
CRISPR Therapeutics
exa-cel
beta thalassemia
NASH on the Cusp: An Emerging Market Opportunity
BioSpace
Mon, 10/23/23 - 09:53 am
NASH
Viking Therapeutics
Madrigal Pharmaceuticals
Terns Pharmaceuticals
Akero Therapeutics
Hepion Pharmaceuticals
Novo Nordisk
Galmed Pharmaceuticals
Madrigal Pursues $500M Public Offering with NASH Market Up for Grabs
BioSpace
Fri, 09/29/23 - 11:58 am
Madrigal Pharmaceuticals
NASH
resmetirom
Madrigal's stock shaken with CEO change up, as Sanofi's Sibold takes the reins
Fierce Biotech
Tue, 09/12/23 - 10:34 am
Madrigal Pharmaceuticals
Pharma CEOs
Sanofi
Bill Sibold
NASH
The 10 highest value R&D projects in biopharma
Fierce Biotech
Wed, 09/6/23 - 10:17 am
R&D
biotech
Merck
sotatercept
Daiichi Sankyo
AstraZeneca
Dato-DXd
Novo Nordisk
CagriSema
Eli Lilly
donanemab
Karuna Therapeutics
Zai Lab
KarXT
Moderna Therapeutics
mRNA-1647
Novartis
iptacopan
Madrigal Pharmaceuticals
resmetirom
Cytokinetics
aficamten
Roche
Chugai
tiragolumab
3 Biotechs Compete for the Same $108-Billion-Dollar Market
Motley Fool
Wed, 08/23/23 - 10:06 am
NASH
Madrigal Pharmaceuticals
Terns Pharmaceuticals
Viking Therapeutics
Prospective NASH market flips to over crowded as Big Pharma GLP-1s cast shadow over biotech breakthroughs
Fierce Biotech
Thu, 08/10/23 - 09:54 am
NASH
Terns Pharmaceuticals
Madrigal Pharmaceuticals
Viking Therapeutics
Unpartnered assets: on the shelf or hidden treasure?
EP Vantage
Thu, 06/15/23 - 09:54 am
R&D
ALX Oncology
Argenx
Ascendis Pharma
Cytokinetics
Karuna Therapeutics
Madrigal Pharmaceuticals
Protagonist Therapeutics
Prothena
Ultragenyx Pharmaceutical
Unique Pharma
Ventyx Biosciences
3 Biotechs That Might Get Bought Out in 2023
Motley Fool
Wed, 04/26/23 - 05:41 pm
M&A
Madrigal Pharmaceuticals
Amylyx
Aurinia Pharmaceuticals
89Bio Enlivened by Nash success
EP Vantage
Thu, 03/23/23 - 09:50 am
89Bio
NASH
Akero Therapeutics
pegozafermin
INTERCEPT
Madrigal Pharmaceuticals
Spotlight – What is next in Nash
EP Vantage
Fri, 03/3/23 - 10:02 am
NASH
clinical trials
89Bio
Arrowhead Pharmaceuticals
Can-Fite BioPharma
Ewopharma
Hepagene Therapeutics
JNJ
Ligand Pharmaceuticals
Madrigal Pharmaceuticals
Merck
NGM Biopharmaceuticals
NorthSea Therapeutics
Novartis
Sagimet Biosciences
Terns Pharmaceuticals
Viking Therapeutics
Big caps bounce back for biopharma
EP Vantage
Mon, 01/16/23 - 11:14 am
pharma stocks
Amgen
BeiGene
Bristol Myers Squibb
Gilead Sciences
Lantheus Holdings
Madrigal Pharmaceuticals
Merck
Moderna Therapeutics
Novo Nordisk
Prometheus Biosciences
Roche
Madrigal shares triple on positive NASH study results
BioPharma Dive
Mon, 12/19/22 - 12:22 pm
Madrigal Pharmaceuticals
clinical trials
NASH
resmetirom
NASH: Wall Street’s Forgotten Mega Blockbuster Indication
BioSpace
Mon, 12/12/22 - 10:13 am
NASH
Intercept Pharma
Novo Nordisk
Madrigal Pharmaceuticals
Inventiva
Galmed Pharmaceuticals
A NASH player touts positive PhIII data, but true test still lies ahead
Endpoints
Mon, 01/31/22 - 11:04 am
NASH
clinical trials
Madrigal Pharmaceuticals
resmetirom
NAFLD
Pages
1
2
next ›
last »